Chemicals
Showing 14101–14250 of 41137 results
-
![An S1P1 modulator (EC50 = 1 nM in a [35S]GTPɣS binding assay); selective for S1P1 over S1P2](https://interpriseusa.com/wp-content/uploads/2021/06/29665.png)
Cenerimod is a sphingosine-1-phosphate receptor 1 (S1P1) modulator with an EC50 value of 1 nM in a [35S]GTPɣS binding assay.{52269} It is selective for S1P1 over S1P2, -3, -4, and -5 (EC50s = >10,000, 228, 2,137, and 36 nM, respectively). Cenerimod (5 µM) decreases TGF-β-induced increases in collagen levels in primary mouse skin fibroblasts.{52270} It inhibits CD4+ T cell, CD8+ T cell, and CD11b+ cell infiltration, reduces IL1b, Il6, and Il13 expression, as well as decreases fibrosis in the skin of a mouse model of sclerodermatous chronic graft versus host disease induced by allogenic bone marrow transplant when administered at a dose of 10 mg/kg per day. Cenerimod (6 mg/kg per day for 32 days) reduces paralysis and spinal cord demyelination in a mouse model of experimental autoimmune encephalitis (EAE).
Brand:CaymanSKU:29665 - 25 mgAvailable on backorder
Cenerimod is a sphingosine-1-phosphate receptor 1 (S1P1) modulator with an EC50 value of 1 nM in a [35S]GTPɣS binding assay.{52269} It is selective for S1P1 over S1P2, -3, -4, and -5 (EC50s = >10,000, 228, 2,137, and 36 nM, respectively). Cenerimod (5 µM) decreases TGF-β-induced increases in collagen levels in primary mouse skin fibroblasts.{52270} It inhibits CD4+ T cell, CD8+ T cell, and CD11b+ cell infiltration, reduces IL1b, Il6, and Il13 expression, as well as decreases fibrosis in the skin of a mouse model of sclerodermatous chronic graft versus host disease induced by allogenic bone marrow transplant when administered at a dose of 10 mg/kg per day. Cenerimod (6 mg/kg per day for 32 days) reduces paralysis and spinal cord demyelination in a mouse model of experimental autoimmune encephalitis (EAE).
Brand:CaymanSKU:29665 - 5 mgAvailable on backorder
Cenicriviroc is an orally bioavailable antagonist of C-C chemokine receptor type 5 (CCR5) and CCR2 that inhibits binding of macrophage inflammatory protein 1α (MIP-1α; IC50 = 2.3 nM) and monocyte chemotactic protein 1 (MCP-1; IC50 = 5.9 nM), respectively, in CHO cells.{41586} Cenicriviroc is also an antagonist of CCR3 and CCR4 (IC50s = 2.4 and 1.1 μM, respectively), however, it does not inhibit agonist binding to CCR1 or CCR7 at concentrations up to 10 μM. At a concentration of 100 nM, cenicriviroc completely inhibits replication of R5 HIV-1 in U87.CD4.CCR5 cells. Cenicriviroc inhibits replication of the R5 HIV-1 strains JR-FL and KK in peripheral blood mononuclear cells (PBMCs) with EC50 values ranging from 21 to 210 pM and 33 to 91 pM, respectively. In vivo, cenicriviroc (20 mg/kg per day) reduces collagen deposition, levels of collagen type 1 protein and mRNA expression, and non-alcoholic fatty liver disease activity score in a mouse model of non-alcoholic steatohepatitis (NASH).{41587} It also reduces collagen type 1 protein levels, mRNA expression, and collagen deposition in a mouse model of unilateral ureter obstruction and a rat model of thioacetamide-induced liver fibrosis.
Brand:CaymanSKU:23927 - 1 mgAvailable on backorder
Cenicriviroc is an orally bioavailable antagonist of C-C chemokine receptor type 5 (CCR5) and CCR2 that inhibits binding of macrophage inflammatory protein 1α (MIP-1α; IC50 = 2.3 nM) and monocyte chemotactic protein 1 (MCP-1; IC50 = 5.9 nM), respectively, in CHO cells.{41586} Cenicriviroc is also an antagonist of CCR3 and CCR4 (IC50s = 2.4 and 1.1 μM, respectively), however, it does not inhibit agonist binding to CCR1 or CCR7 at concentrations up to 10 μM. At a concentration of 100 nM, cenicriviroc completely inhibits replication of R5 HIV-1 in U87.CD4.CCR5 cells. Cenicriviroc inhibits replication of the R5 HIV-1 strains JR-FL and KK in peripheral blood mononuclear cells (PBMCs) with EC50 values ranging from 21 to 210 pM and 33 to 91 pM, respectively. In vivo, cenicriviroc (20 mg/kg per day) reduces collagen deposition, levels of collagen type 1 protein and mRNA expression, and non-alcoholic fatty liver disease activity score in a mouse model of non-alcoholic steatohepatitis (NASH).{41587} It also reduces collagen type 1 protein levels, mRNA expression, and collagen deposition in a mouse model of unilateral ureter obstruction and a rat model of thioacetamide-induced liver fibrosis.
Brand:CaymanSKU:23927 - 10 mgAvailable on backorder
Cenicriviroc is an orally bioavailable antagonist of C-C chemokine receptor type 5 (CCR5) and CCR2 that inhibits binding of macrophage inflammatory protein 1α (MIP-1α; IC50 = 2.3 nM) and monocyte chemotactic protein 1 (MCP-1; IC50 = 5.9 nM), respectively, in CHO cells.{41586} Cenicriviroc is also an antagonist of CCR3 and CCR4 (IC50s = 2.4 and 1.1 μM, respectively), however, it does not inhibit agonist binding to CCR1 or CCR7 at concentrations up to 10 μM. At a concentration of 100 nM, cenicriviroc completely inhibits replication of R5 HIV-1 in U87.CD4.CCR5 cells. Cenicriviroc inhibits replication of the R5 HIV-1 strains JR-FL and KK in peripheral blood mononuclear cells (PBMCs) with EC50 values ranging from 21 to 210 pM and 33 to 91 pM, respectively. In vivo, cenicriviroc (20 mg/kg per day) reduces collagen deposition, levels of collagen type 1 protein and mRNA expression, and non-alcoholic fatty liver disease activity score in a mouse model of non-alcoholic steatohepatitis (NASH).{41587} It also reduces collagen type 1 protein levels, mRNA expression, and collagen deposition in a mouse model of unilateral ureter obstruction and a rat model of thioacetamide-induced liver fibrosis.
Brand:CaymanSKU:23927 - 5 mgAvailable on backorder
Cenicriviroc is an orally bioavailable antagonist of C-C chemokine receptor type 5 (CCR5) and CCR2 that inhibits binding of macrophage inflammatory protein 1α (MIP-1α; IC50 = 2.3 nM) and monocyte chemotactic protein 1 (MCP-1; IC50 = 5.9 nM), respectively, in CHO cells.{41586} Cenicriviroc is also an antagonist of CCR3 and CCR4 (IC50s = 2.4 and 1.1 μM, respectively), however, it does not inhibit agonist binding to CCR1 or CCR7 at concentrations up to 10 μM. At a concentration of 100 nM, cenicriviroc completely inhibits replication of R5 HIV-1 in U87.CD4.CCR5 cells. Cenicriviroc inhibits replication of the R5 HIV-1 strains JR-FL and KK in peripheral blood mononuclear cells (PBMCs) with EC50 values ranging from 21 to 210 pM and 33 to 91 pM, respectively. In vivo, cenicriviroc (20 mg/kg per day) reduces collagen deposition, levels of collagen type 1 protein and mRNA expression, and non-alcoholic fatty liver disease activity score in a mouse model of non-alcoholic steatohepatitis (NASH).{41587} It also reduces collagen type 1 protein levels, mRNA expression, and collagen deposition in a mouse model of unilateral ureter obstruction and a rat model of thioacetamide-induced liver fibrosis.
Brand:CaymanSKU:23927 - 500 µgAvailable on backorder
CENTA is a colorimetric cephalosporin substrate for β-lactamases.{58099,58100} Upon hydrolysis by β-lacatamases, CENTA turns from light yellow to chrome yellow, which can be quantified by colorimetric detection at 405 nm as a measure of β-lactamase activity.
Brand:CaymanSKU:31534 - 1 mgAvailable on backorder
CENTA is a colorimetric cephalosporin substrate for β-lactamases.{58099,58100} Upon hydrolysis by β-lacatamases, CENTA turns from light yellow to chrome yellow, which can be quantified by colorimetric detection at 405 nm as a measure of β-lactamase activity.
Brand:CaymanSKU:31534 - 5 mgAvailable on backorder
CEP-28122 is a potent inhibitor of anaplastic lymphoma kinase (ALK; IC50 = 1.9 nM) that less potently inhibits other tyrosine and serine/threonine kinases.{31619} It blocks the phosphorylation of ALK and other ALK substrates in cells and induces concentration-dependent growth inhibition or cytotoxicity of ALK-positive cancer cells.{31619} CEP-28122 is orally active, inhibiting ALK tyrosine phosphorylation in tumor xenografts in mice for more than 12 hours following single oral dosing at 30 mg/kg.{31619}
Brand:CaymanSKU:-Available on backorder
CEP-28122 is a potent inhibitor of anaplastic lymphoma kinase (ALK; IC50 = 1.9 nM) that less potently inhibits other tyrosine and serine/threonine kinases.{31619} It blocks the phosphorylation of ALK and other ALK substrates in cells and induces concentration-dependent growth inhibition or cytotoxicity of ALK-positive cancer cells.{31619} CEP-28122 is orally active, inhibiting ALK tyrosine phosphorylation in tumor xenografts in mice for more than 12 hours following single oral dosing at 30 mg/kg.{31619}
Brand:CaymanSKU:-Available on backorder
CEP-28122 is a potent inhibitor of anaplastic lymphoma kinase (ALK; IC50 = 1.9 nM) that less potently inhibits other tyrosine and serine/threonine kinases.{31619} It blocks the phosphorylation of ALK and other ALK substrates in cells and induces concentration-dependent growth inhibition or cytotoxicity of ALK-positive cancer cells.{31619} CEP-28122 is orally active, inhibiting ALK tyrosine phosphorylation in tumor xenografts in mice for more than 12 hours following single oral dosing at 30 mg/kg.{31619}
Brand:CaymanSKU:-Available on backorder
CEP-28122 is a potent inhibitor of anaplastic lymphoma kinase (ALK; IC50 = 1.9 nM) that less potently inhibits other tyrosine and serine/threonine kinases.{31619} It blocks the phosphorylation of ALK and other ALK substrates in cells and induces concentration-dependent growth inhibition or cytotoxicity of ALK-positive cancer cells.{31619} CEP-28122 is orally active, inhibiting ALK tyrosine phosphorylation in tumor xenografts in mice for more than 12 hours following single oral dosing at 30 mg/kg.{31619}
Brand:CaymanSKU:-Available on backorder
B-Raf is a MAP kinase kinase kinase, which functions downstream of Ras family GTPases to activate MEK1/2 and ERK1/2 signaling.{27148} Mutations of B-Raf, particularly at Val600, are common in melanomas and melanocytic nevi.{27148} CEP-32496 is a potent inhibitor of B-RafV600E (Kd = 14 nM in an in vitro binding assay).{30907} It blocks B-RafV600E-dependent phosphorylation of MEK in human melanoma A375 and colorectal cancer COLO 205 cells (IC50s = 78 and 60 nM, respectively).{30907} CEP-32496 binds kinases other than B-Raf but displays selective cytotoxicity for cells expressing B-RafV600E.{30907} It displays good oral bioavailability in rats, dogs, and monkeys and has single oral dose pharmacodynamics inhibition of both pMEK and pERK in B-RafV600E colon carcinoma xenografts in nude mice.{30907}
Brand:CaymanSKU:-Available on backorder
B-Raf is a MAP kinase kinase kinase, which functions downstream of Ras family GTPases to activate MEK1/2 and ERK1/2 signaling.{27148} Mutations of B-Raf, particularly at Val600, are common in melanomas and melanocytic nevi.{27148} CEP-32496 is a potent inhibitor of B-RafV600E (Kd = 14 nM in an in vitro binding assay).{30907} It blocks B-RafV600E-dependent phosphorylation of MEK in human melanoma A375 and colorectal cancer COLO 205 cells (IC50s = 78 and 60 nM, respectively).{30907} CEP-32496 binds kinases other than B-Raf but displays selective cytotoxicity for cells expressing B-RafV600E.{30907} It displays good oral bioavailability in rats, dogs, and monkeys and has single oral dose pharmacodynamics inhibition of both pMEK and pERK in B-RafV600E colon carcinoma xenografts in nude mice.{30907}
Brand:CaymanSKU:-Available on backorder
B-Raf is a MAP kinase kinase kinase, which functions downstream of Ras family GTPases to activate MEK1/2 and ERK1/2 signaling.{27148} Mutations of B-Raf, particularly at Val600, are common in melanomas and melanocytic nevi.{27148} CEP-32496 is a potent inhibitor of B-RafV600E (Kd = 14 nM in an in vitro binding assay).{30907} It blocks B-RafV600E-dependent phosphorylation of MEK in human melanoma A375 and colorectal cancer COLO 205 cells (IC50s = 78 and 60 nM, respectively).{30907} CEP-32496 binds kinases other than B-Raf but displays selective cytotoxicity for cells expressing B-RafV600E.{30907} It displays good oral bioavailability in rats, dogs, and monkeys and has single oral dose pharmacodynamics inhibition of both pMEK and pERK in B-RafV600E colon carcinoma xenografts in nude mice.{30907}
Brand:CaymanSKU:-Available on backorder
B-Raf is a MAP kinase kinase kinase, which functions downstream of Ras family GTPases to activate MEK1/2 and ERK1/2 signaling.{27148} Mutations of B-Raf, particularly at Val600, are common in melanomas and melanocytic nevi.{27148} CEP-32496 is a potent inhibitor of B-RafV600E (Kd = 14 nM in an in vitro binding assay).{30907} It blocks B-RafV600E-dependent phosphorylation of MEK in human melanoma A375 and colorectal cancer COLO 205 cells (IC50s = 78 and 60 nM, respectively).{30907} CEP-32496 binds kinases other than B-Raf but displays selective cytotoxicity for cells expressing B-RafV600E.{30907} It displays good oral bioavailability in rats, dogs, and monkeys and has single oral dose pharmacodynamics inhibition of both pMEK and pERK in B-RafV600E colon carcinoma xenografts in nude mice.{30907}
Brand:CaymanSKU:-Available on backorder
Janus kinases (JAKs) are non-receptor kinases that mediate signaling through cytokine receptors, often to members of the signal transducer and activator of transcription family.{20362} CEP-33779 is a potent, orally available inhibitor of JAK2 (IC50 = 1.3 nM).{27702} It shows 65-fold selectivity for JAK2 over JAK3.{27702} In mouse models of systemic lupus erythematosus, CEP-33779 reduces the production of inflammatory cytokines, decreases splenomegaly and lymphomegaly, and extends survival.{27702} It also diminishes inflammatory signaling and improves clinical scores in mice during collagen antibody-induced arthritis and collagen type II-induced arthritis.{27701} CEP-33779 induces regression of established colorectal tumors in mice, reducing angiogenesis and proliferation of tumor cells.{27700}
Brand:CaymanSKU:-Out of stock
Janus kinases (JAKs) are non-receptor kinases that mediate signaling through cytokine receptors, often to members of the signal transducer and activator of transcription family.{20362} CEP-33779 is a potent, orally available inhibitor of JAK2 (IC50 = 1.3 nM).{27702} It shows 65-fold selectivity for JAK2 over JAK3.{27702} In mouse models of systemic lupus erythematosus, CEP-33779 reduces the production of inflammatory cytokines, decreases splenomegaly and lymphomegaly, and extends survival.{27702} It also diminishes inflammatory signaling and improves clinical scores in mice during collagen antibody-induced arthritis and collagen type II-induced arthritis.{27701} CEP-33779 induces regression of established colorectal tumors in mice, reducing angiogenesis and proliferation of tumor cells.{27700}
Brand:CaymanSKU:-Out of stock
Janus kinases (JAKs) are non-receptor kinases that mediate signaling through cytokine receptors, often to members of the signal transducer and activator of transcription family.{20362} CEP-33779 is a potent, orally available inhibitor of JAK2 (IC50 = 1.3 nM).{27702} It shows 65-fold selectivity for JAK2 over JAK3.{27702} In mouse models of systemic lupus erythematosus, CEP-33779 reduces the production of inflammatory cytokines, decreases splenomegaly and lymphomegaly, and extends survival.{27702} It also diminishes inflammatory signaling and improves clinical scores in mice during collagen antibody-induced arthritis and collagen type II-induced arthritis.{27701} CEP-33779 induces regression of established colorectal tumors in mice, reducing angiogenesis and proliferation of tumor cells.{27700}
Brand:CaymanSKU:-Out of stock
CEP-37440 is a dual inhibitor of focal adhesion kinase 1 (FAK1; IC50s = 2.0 and 80 nM for in vitro enzyme and cellular inhibition, respectively) and anaplastic lymphoma kinase (ALK; IC50s = 3.1 and 22 nM for in vitro enzyme and cellular inhibition, respectively).{33407,33408} It blocks the proliferation of inflammatory and triple-negative breast cancer cell lines but not normal breast epithelial cells.{33408} CEP-37440 reduces the growth and metastasis of breast cancer xenografts in mice when given by oral gavage.{33408}
Brand:CaymanSKU:21278 -Out of stock
CEP-37440 is a dual inhibitor of focal adhesion kinase 1 (FAK1; IC50s = 2.0 and 80 nM for in vitro enzyme and cellular inhibition, respectively) and anaplastic lymphoma kinase (ALK; IC50s = 3.1 and 22 nM for in vitro enzyme and cellular inhibition, respectively).{33407,33408} It blocks the proliferation of inflammatory and triple-negative breast cancer cell lines but not normal breast epithelial cells.{33408} CEP-37440 reduces the growth and metastasis of breast cancer xenografts in mice when given by oral gavage.{33408}
Brand:CaymanSKU:21278 -Out of stock
CEP-37440 is a dual inhibitor of focal adhesion kinase 1 (FAK1; IC50s = 2.0 and 80 nM for in vitro enzyme and cellular inhibition, respectively) and anaplastic lymphoma kinase (ALK; IC50s = 3.1 and 22 nM for in vitro enzyme and cellular inhibition, respectively).{33407,33408} It blocks the proliferation of inflammatory and triple-negative breast cancer cell lines but not normal breast epithelial cells.{33408} CEP-37440 reduces the growth and metastasis of breast cancer xenografts in mice when given by oral gavage.{33408}
Brand:CaymanSKU:21278 -Out of stock
CEP-37440 is a dual inhibitor of focal adhesion kinase 1 (FAK1; IC50s = 2.0 and 80 nM for in vitro enzyme and cellular inhibition, respectively) and anaplastic lymphoma kinase (ALK; IC50s = 3.1 and 22 nM for in vitro enzyme and cellular inhibition, respectively).{33407,33408} It blocks the proliferation of inflammatory and triple-negative breast cancer cell lines but not normal breast epithelial cells.{33408} CEP-37440 reduces the growth and metastasis of breast cancer xenografts in mice when given by oral gavage.{33408}
Brand:CaymanSKU:21278 -Out of stock
CEP-40783 is an inhibitor of the receptor tyrosine kinases Axl and c-MET (IC50s = 7 and 12 nM, respectively).{43937} It inhibits Axl in 293GT cells expressing Axl and c-MET in NCI H1299 non-small cell lung cancer (NSCLC) cells with IC50 values of 0.26 and 6 nM, respectively. It also inhibits the receptor tyrosine kinases TYRO3 and MER (IC50s = 3.5 and 1.89 nM, respectively).{43938} CEP-40783 (0.3 mg/kg) induces complete regression of tumors in an Axl/NIH3T3 mouse xenograft model and reduces the metastatic tumor burden in mouse orthotopic breast cancer models. It also induces tumor stasis and regression in an EBC-1 NSCLC mouse xenograft model when administered at doses of 3 and 10 mg/kg, respectively. CEP-40783 reduces tumor growth in an MC38 mouse syngeneic model concomitantly with an increase in leukocyte infiltration into tumors, the production of IFN-γ in natural killer cells, and the percentage of CD8+ T cells in tumor tissue.{43938}
Brand:CaymanSKU:25749 - 1 mgAvailable on backorder
CEP-40783 is an inhibitor of the receptor tyrosine kinases Axl and c-MET (IC50s = 7 and 12 nM, respectively).{43937} It inhibits Axl in 293GT cells expressing Axl and c-MET in NCI H1299 non-small cell lung cancer (NSCLC) cells with IC50 values of 0.26 and 6 nM, respectively. It also inhibits the receptor tyrosine kinases TYRO3 and MER (IC50s = 3.5 and 1.89 nM, respectively).{43938} CEP-40783 (0.3 mg/kg) induces complete regression of tumors in an Axl/NIH3T3 mouse xenograft model and reduces the metastatic tumor burden in mouse orthotopic breast cancer models. It also induces tumor stasis and regression in an EBC-1 NSCLC mouse xenograft model when administered at doses of 3 and 10 mg/kg, respectively. CEP-40783 reduces tumor growth in an MC38 mouse syngeneic model concomitantly with an increase in leukocyte infiltration into tumors, the production of IFN-γ in natural killer cells, and the percentage of CD8+ T cells in tumor tissue.{43938}
Brand:CaymanSKU:25749 - 10 mgAvailable on backorder
CEP-40783 is an inhibitor of the receptor tyrosine kinases Axl and c-MET (IC50s = 7 and 12 nM, respectively).{43937} It inhibits Axl in 293GT cells expressing Axl and c-MET in NCI H1299 non-small cell lung cancer (NSCLC) cells with IC50 values of 0.26 and 6 nM, respectively. It also inhibits the receptor tyrosine kinases TYRO3 and MER (IC50s = 3.5 and 1.89 nM, respectively).{43938} CEP-40783 (0.3 mg/kg) induces complete regression of tumors in an Axl/NIH3T3 mouse xenograft model and reduces the metastatic tumor burden in mouse orthotopic breast cancer models. It also induces tumor stasis and regression in an EBC-1 NSCLC mouse xenograft model when administered at doses of 3 and 10 mg/kg, respectively. CEP-40783 reduces tumor growth in an MC38 mouse syngeneic model concomitantly with an increase in leukocyte infiltration into tumors, the production of IFN-γ in natural killer cells, and the percentage of CD8+ T cells in tumor tissue.{43938}
Brand:CaymanSKU:25749 - 25 mgAvailable on backorder
CEP-40783 is an inhibitor of the receptor tyrosine kinases Axl and c-MET (IC50s = 7 and 12 nM, respectively).{43937} It inhibits Axl in 293GT cells expressing Axl and c-MET in NCI H1299 non-small cell lung cancer (NSCLC) cells with IC50 values of 0.26 and 6 nM, respectively. It also inhibits the receptor tyrosine kinases TYRO3 and MER (IC50s = 3.5 and 1.89 nM, respectively).{43938} CEP-40783 (0.3 mg/kg) induces complete regression of tumors in an Axl/NIH3T3 mouse xenograft model and reduces the metastatic tumor burden in mouse orthotopic breast cancer models. It also induces tumor stasis and regression in an EBC-1 NSCLC mouse xenograft model when administered at doses of 3 and 10 mg/kg, respectively. CEP-40783 reduces tumor growth in an MC38 mouse syngeneic model concomitantly with an increase in leukocyte infiltration into tumors, the production of IFN-γ in natural killer cells, and the percentage of CD8+ T cells in tumor tissue.{43938}
Brand:CaymanSKU:25749 - 5 mgAvailable on backorder
Cephaeline is an alkaloid originally isolated from C. ipecacuanha with diverse biological activities.{36703,36704,36705,36706} It inhibits the cytochrome P450 (CYP) isoforms CYP2D6 and CYP3A4 in vitro (Kis = 54 and 355 μM, respectively).{36703} Cephaeline reduces Zika virus (ZIKV) NS1 protein expression in HEK293 cells (IC50 = 26.4 nM) and reduces viral titer in ZIKV-infected SNB-19 cells (IC50 = 3.11 nM).{36704} In vivo, cephaeline (2 mg/kg, i.p.) reduces serum viral load in ZIKV-infected Ifnar1-/- mice. It induces emesis in ferrets when administered at a dose of 0.5 mg/kg, an effect that is prevented by the serotonin (5-HT) receptor subtype 5-HT3 antagonist ondansetron.{36705} Cephaeline (1 mg/kg) also increases output of respiratory tract fluid in rabbits.{36706}
Brand:CaymanSKU:20916 -Out of stock
Cephaeline is an alkaloid originally isolated from C. ipecacuanha with diverse biological activities.{36703,36704,36705,36706} It inhibits the cytochrome P450 (CYP) isoforms CYP2D6 and CYP3A4 in vitro (Kis = 54 and 355 μM, respectively).{36703} Cephaeline reduces Zika virus (ZIKV) NS1 protein expression in HEK293 cells (IC50 = 26.4 nM) and reduces viral titer in ZIKV-infected SNB-19 cells (IC50 = 3.11 nM).{36704} In vivo, cephaeline (2 mg/kg, i.p.) reduces serum viral load in ZIKV-infected Ifnar1-/- mice. It induces emesis in ferrets when administered at a dose of 0.5 mg/kg, an effect that is prevented by the serotonin (5-HT) receptor subtype 5-HT3 antagonist ondansetron.{36705} Cephaeline (1 mg/kg) also increases output of respiratory tract fluid in rabbits.{36706}
Brand:CaymanSKU:20916 -Out of stock
Cephalexin is a cephalosporin antibiotic that is active against most Gram-positive cocci, including penicillinase-producing Staphylococci, and against Gram-negative bacteria such as N. gonorrhoeae, E. coli, K. pneumonia, Salmonellae, Shigella, and some strains of H. influenza.{27468} It is not effective against Proteus species, Pseudomonas, or mycobacteria.{27468} Cephalexin specifically inactivates penicillin-binding protein (PBP) 3, which is essential for bacterial cell wall synthesis.{25731} It has been combined with antibiotics that preferentially target alternate PBP isotypes as a strategy to combat drug-resistant bacteria.{26293}
Brand:CaymanSKU:9002009 - 1 gAvailable on backorder
Cephalexin is a cephalosporin antibiotic that is active against most Gram-positive cocci, including penicillinase-producing Staphylococci, and against Gram-negative bacteria such as N. gonorrhoeae, E. coli, K. pneumonia, Salmonellae, Shigella, and some strains of H. influenza.{27468} It is not effective against Proteus species, Pseudomonas, or mycobacteria.{27468} Cephalexin specifically inactivates penicillin-binding protein (PBP) 3, which is essential for bacterial cell wall synthesis.{25731} It has been combined with antibiotics that preferentially target alternate PBP isotypes as a strategy to combat drug-resistant bacteria.{26293}
Brand:CaymanSKU:9002009 - 10 gAvailable on backorder
Cephalexin is a cephalosporin antibiotic that is active against most Gram-positive cocci, including penicillinase-producing Staphylococci, and against Gram-negative bacteria such as N. gonorrhoeae, E. coli, K. pneumonia, Salmonellae, Shigella, and some strains of H. influenza.{27468} It is not effective against Proteus species, Pseudomonas, or mycobacteria.{27468} Cephalexin specifically inactivates penicillin-binding protein (PBP) 3, which is essential for bacterial cell wall synthesis.{25731} It has been combined with antibiotics that preferentially target alternate PBP isotypes as a strategy to combat drug-resistant bacteria.{26293}
Brand:CaymanSKU:9002009 - 25 gAvailable on backorder
Cephalexin is a cephalosporin antibiotic that is active against most Gram-positive cocci, including penicillinase-producing Staphylococci, and against Gram-negative bacteria such as N. gonorrhoeae, E. coli, K. pneumonia, Salmonellae, Shigella, and some strains of H. influenza.{27468} It is not effective against Proteus species, Pseudomonas, or mycobacteria.{27468} Cephalexin specifically inactivates penicillin-binding protein (PBP) 3, which is essential for bacterial cell wall synthesis.{25731} It has been combined with antibiotics that preferentially target alternate PBP isotypes as a strategy to combat drug-resistant bacteria.{26293}
Brand:CaymanSKU:9002009 - 5 gAvailable on backorder
Cephalomannine is a taxane diterpenoid and a derivative of paclitaxel (Item No. 10461) that has been found in yew trees and taxol-producing fungi.{42881} It inhibits calcium-induced microtubule depolymerization in vitro and increases accumulation of vincristine (Item No. 11764) in multidrug-resistant 2780AD ovarian cancer cells.{42882}
Brand:CaymanSKU:27878 - 1 mgAvailable on backorder
Cephalomannine is a taxane diterpenoid and a derivative of paclitaxel (Item No. 10461) that has been found in yew trees and taxol-producing fungi.{42881} It inhibits calcium-induced microtubule depolymerization in vitro and increases accumulation of vincristine (Item No. 11764) in multidrug-resistant 2780AD ovarian cancer cells.{42882}
Brand:CaymanSKU:27878 - 10 mgAvailable on backorder
Cephalomannine is a taxane diterpenoid and a derivative of paclitaxel (Item No. 10461) that has been found in yew trees and taxol-producing fungi.{42881} It inhibits calcium-induced microtubule depolymerization in vitro and increases accumulation of vincristine (Item No. 11764) in multidrug-resistant 2780AD ovarian cancer cells.{42882}
Brand:CaymanSKU:27878 - 5 mgAvailable on backorder
Cepharanthine is a biscoclaurine alkaloid extracted from S. cepharantha that is cationic and amphipathic and has been reported to decrease the fluidity of biological membranes.{31428} It exhibits antiparasitic, antimalarial, antiviral, anti-inflammatory, antimetastatic, and anticancer activities in various cell and animal models.{31428,31426,31429} Cepharanthine can decrease LPS-stimulated expression of TNF-α, IL-6, and IL-1β in macrophages and prevent the activation of NF-κB, ERK, JNK, and p38 MAPK.{31427} It has also been shown to inhibit cell and tumor growth, inducing G1 phase cell cycle arrest and apoptosis, and decreasing expression of STAT3, Bcl-xL, c-Myc, and cyclin D1 in osteosarcoma models.{31425}
Brand:CaymanSKU:19648 -Available on backorder
Cepharanthine is a biscoclaurine alkaloid extracted from S. cepharantha that is cationic and amphipathic and has been reported to decrease the fluidity of biological membranes.{31428} It exhibits antiparasitic, antimalarial, antiviral, anti-inflammatory, antimetastatic, and anticancer activities in various cell and animal models.{31428,31426,31429} Cepharanthine can decrease LPS-stimulated expression of TNF-α, IL-6, and IL-1β in macrophages and prevent the activation of NF-κB, ERK, JNK, and p38 MAPK.{31427} It has also been shown to inhibit cell and tumor growth, inducing G1 phase cell cycle arrest and apoptosis, and decreasing expression of STAT3, Bcl-xL, c-Myc, and cyclin D1 in osteosarcoma models.{31425}
Brand:CaymanSKU:19648 -Available on backorder
Cepharanthine is a biscoclaurine alkaloid extracted from S. cepharantha that is cationic and amphipathic and has been reported to decrease the fluidity of biological membranes.{31428} It exhibits antiparasitic, antimalarial, antiviral, anti-inflammatory, antimetastatic, and anticancer activities in various cell and animal models.{31428,31426,31429} Cepharanthine can decrease LPS-stimulated expression of TNF-α, IL-6, and IL-1β in macrophages and prevent the activation of NF-κB, ERK, JNK, and p38 MAPK.{31427} It has also been shown to inhibit cell and tumor growth, inducing G1 phase cell cycle arrest and apoptosis, and decreasing expression of STAT3, Bcl-xL, c-Myc, and cyclin D1 in osteosarcoma models.{31425}
Brand:CaymanSKU:19648 -Available on backorder
Cepharanthine is a biscoclaurine alkaloid extracted from S. cepharantha that is cationic and amphipathic and has been reported to decrease the fluidity of biological membranes.{31428} It exhibits antiparasitic, antimalarial, antiviral, anti-inflammatory, antimetastatic, and anticancer activities in various cell and animal models.{31428,31426,31429} Cepharanthine can decrease LPS-stimulated expression of TNF-α, IL-6, and IL-1β in macrophages and prevent the activation of NF-κB, ERK, JNK, and p38 MAPK.{31427} It has also been shown to inhibit cell and tumor growth, inducing G1 phase cell cycle arrest and apoptosis, and decreasing expression of STAT3, Bcl-xL, c-Myc, and cyclin D1 in osteosarcoma models.{31425}
Brand:CaymanSKU:19648 -Available on backorder
Ceralifimod is an agonist of the sphingosine-1-phosphate (S1P) receptors S1P1 and S1P5 (Kis = 0.626 and 0.574 nM, respectively).{40578} It is selective for S1P1 and S1P5 over S1P2-4 (Kis = >5,450, >5,630, and 28.8 nM, respectively). Ceralifimod induces calcium influx in CHO-K1 cells overexpressing S1P1 (EC50 = 1 nM) and cAMP accumulation in CHO-K1 cells overexpressing S1P1 or S1P5 (EC50s = 0.027 and 0.33 nM, respectively). In vivo, ceralifimod (0.03 and 0.1 mg/kg) reduces paw edema in a rat model of collagen induced arthritis (CIA). It also delays disease onset and inhibits lymphocyte infiltration of the spinal cord in a rat model of experimental autoimmune encephalomyelitis (EAE) and prevents disease relapse in a non-obese diabetic mouse model of relapsing-remitting EAE.{41833}
Brand:CaymanSKU:24159 - 1 mgAvailable on backorder
Ceralifimod is an agonist of the sphingosine-1-phosphate (S1P) receptors S1P1 and S1P5 (Kis = 0.626 and 0.574 nM, respectively).{40578} It is selective for S1P1 and S1P5 over S1P2-4 (Kis = >5,450, >5,630, and 28.8 nM, respectively). Ceralifimod induces calcium influx in CHO-K1 cells overexpressing S1P1 (EC50 = 1 nM) and cAMP accumulation in CHO-K1 cells overexpressing S1P1 or S1P5 (EC50s = 0.027 and 0.33 nM, respectively). In vivo, ceralifimod (0.03 and 0.1 mg/kg) reduces paw edema in a rat model of collagen induced arthritis (CIA). It also delays disease onset and inhibits lymphocyte infiltration of the spinal cord in a rat model of experimental autoimmune encephalomyelitis (EAE) and prevents disease relapse in a non-obese diabetic mouse model of relapsing-remitting EAE.{41833}
Brand:CaymanSKU:24159 - 10 mgAvailable on backorder
Ceralifimod is an agonist of the sphingosine-1-phosphate (S1P) receptors S1P1 and S1P5 (Kis = 0.626 and 0.574 nM, respectively).{40578} It is selective for S1P1 and S1P5 over S1P2-4 (Kis = >5,450, >5,630, and 28.8 nM, respectively). Ceralifimod induces calcium influx in CHO-K1 cells overexpressing S1P1 (EC50 = 1 nM) and cAMP accumulation in CHO-K1 cells overexpressing S1P1 or S1P5 (EC50s = 0.027 and 0.33 nM, respectively). In vivo, ceralifimod (0.03 and 0.1 mg/kg) reduces paw edema in a rat model of collagen induced arthritis (CIA). It also delays disease onset and inhibits lymphocyte infiltration of the spinal cord in a rat model of experimental autoimmune encephalomyelitis (EAE) and prevents disease relapse in a non-obese diabetic mouse model of relapsing-remitting EAE.{41833}
Brand:CaymanSKU:24159 - 25 mgAvailable on backorder
Ceralifimod is an agonist of the sphingosine-1-phosphate (S1P) receptors S1P1 and S1P5 (Kis = 0.626 and 0.574 nM, respectively).{40578} It is selective for S1P1 and S1P5 over S1P2-4 (Kis = >5,450, >5,630, and 28.8 nM, respectively). Ceralifimod induces calcium influx in CHO-K1 cells overexpressing S1P1 (EC50 = 1 nM) and cAMP accumulation in CHO-K1 cells overexpressing S1P1 or S1P5 (EC50s = 0.027 and 0.33 nM, respectively). In vivo, ceralifimod (0.03 and 0.1 mg/kg) reduces paw edema in a rat model of collagen induced arthritis (CIA). It also delays disease onset and inhibits lymphocyte infiltration of the spinal cord in a rat model of experimental autoimmune encephalomyelitis (EAE) and prevents disease relapse in a non-obese diabetic mouse model of relapsing-remitting EAE.{41833}
Brand:CaymanSKU:24159 - 5 mgAvailable on backorder
The ceramides mixture consists of hydroxy and non-hydroxy fatty acid-containing ceramides. Ceramides are generated from sphingomyelin through activation of sphingomyelinases or through the de novo synthesis pathway, which requires the coordinated action of serine palmitoyl transferase and ceramide synthase. They have been shown to mediate antiproliferative responses such as apoptosis, growth arrest, differentiation, and senescence.{19146} [Matreya, LLC. Catalog No. 1056]
Brand:CaymanSKU:22853 -Out of stock
Ceranib-2 is a ceramidase inhibitor that inhibits ceramidase activity (IC50 = 28 μM in SKOV3 cells).{19996} It also increases intracellular accumulation of various ceramides, including C14 ceramide (Item No. 22531), C24 ceramide (Item No. 62535), C26 ceramide, and C26:1 ceramide, and total ceramide levels and decreases levels of dihydrosphingosine, sphingosine, and sphingosine-1-phosphate (Item No. 22500) in SKOV3 cells. In vivo, ceranib-2 (20 and 50 mg/kg, i.p.) reduces tumor volume in a JC mammary adenocarcinoma mouse syngeneic tumor model.
Brand:CaymanSKU:11092 - 10 mgAvailable on backorder
Ceranib-2 is a ceramidase inhibitor that inhibits ceramidase activity (IC50 = 28 μM in SKOV3 cells).{19996} It also increases intracellular accumulation of various ceramides, including C14 ceramide (Item No. 22531), C24 ceramide (Item No. 62535), C26 ceramide, and C26:1 ceramide, and total ceramide levels and decreases levels of dihydrosphingosine, sphingosine, and sphingosine-1-phosphate (Item No. 22500) in SKOV3 cells. In vivo, ceranib-2 (20 and 50 mg/kg, i.p.) reduces tumor volume in a JC mammary adenocarcinoma mouse syngeneic tumor model.
Brand:CaymanSKU:11092 - 25 mgAvailable on backorder
Ceranib-2 is a ceramidase inhibitor that inhibits ceramidase activity (IC50 = 28 μM in SKOV3 cells).{19996} It also increases intracellular accumulation of various ceramides, including C14 ceramide (Item No. 22531), C24 ceramide (Item No. 62535), C26 ceramide, and C26:1 ceramide, and total ceramide levels and decreases levels of dihydrosphingosine, sphingosine, and sphingosine-1-phosphate (Item No. 22500) in SKOV3 cells. In vivo, ceranib-2 (20 and 50 mg/kg, i.p.) reduces tumor volume in a JC mammary adenocarcinoma mouse syngeneic tumor model.
Brand:CaymanSKU:11092 - 5 mgAvailable on backorder
Ceranib-2 is a ceramidase inhibitor that inhibits ceramidase activity (IC50 = 28 μM in SKOV3 cells).{19996} It also increases intracellular accumulation of various ceramides, including C14 ceramide (Item No. 22531), C24 ceramide (Item No. 62535), C26 ceramide, and C26:1 ceramide, and total ceramide levels and decreases levels of dihydrosphingosine, sphingosine, and sphingosine-1-phosphate (Item No. 22500) in SKOV3 cells. In vivo, ceranib-2 (20 and 50 mg/kg, i.p.) reduces tumor volume in a JC mammary adenocarcinoma mouse syngeneic tumor model.
Brand:CaymanSKU:11092 - 50 mgAvailable on backorder
Cercosporamide is a natural antifungal phytotoxin isolated from the Cercosporidium fungus, which infects the leaves of cassava plants.{25074} Its antifungal effect results from its selective and potent inhibition of fungal PKC-like 1 kinases (Pkc1), which are central to cell wall integrity (IC50 = 25 nM for Candida Pkc1).{25072} Cercosporamide less effectively inhibits human PKC isoforms PKCα, β, and γ (IC50s = 1.02, 0.35, and 5.8 μM, respectively), an action linked to lowering of plasma glucose in hyperglycemic mice.{25072,25075} However, it potently inhibits MAPK-interacting kinases Mnk1 and Mnk2 (IC50 = 115 and 11 nM, respectively), reducing protein translation in cancer cells.{25071,25073} Cercosporamide is orally bioavailable.{25072,25075}
Brand:CaymanSKU:- Cercosporamide is a natural antifungal phytotoxin isolated from the Cercosporidium fungus, which infects the leaves of cassava plants.{25074} Its antifungal effect results from its selective and potent inhibition of fungal PKC-like 1 kinases (Pkc1), which are central to cell wall integrity (IC50 = 25 nM for Candida Pkc1).{25072} Cercosporamide less effectively inhibits human PKC isoforms PKCα, β, and γ (IC50s = 1.02, 0.35, and 5.8 μM, respectively), an action linked to lowering of plasma glucose in hyperglycemic mice.{25072,25075} However, it potently inhibits MAPK-interacting kinases Mnk1 and Mnk2 (IC50 = 115 and 11 nM, respectively), reducing protein translation in cancer cells.{25071,25073} Cercosporamide is orally bioavailable.{25072,25075}
Brand:CaymanSKU:-
Cercosporin is a pigmented phytotoxin isolated from the fungus C. kikuchii that produces reactive oxygen species in plant hosts leading to cellular damage.{37038,37041} It exhibits light-activated cytotoxic effects in vitro with cytotoxic concentration (CC50) values of 241, 282, and 174 nM in HeLa, A432, and MCF-7 cells, respectively.{37040} It is a selective inhibitor of PKC (IC50 = 600-1,300 nM) with no activity on PKA or PPK at concentrations over 180 µM.{37039}
Brand:CaymanSKU:22175 -Out of stock
Cercosporin is a pigmented phytotoxin isolated from the fungus C. kikuchii that produces reactive oxygen species in plant hosts leading to cellular damage.{37038,37041} It exhibits light-activated cytotoxic effects in vitro with cytotoxic concentration (CC50) values of 241, 282, and 174 nM in HeLa, A432, and MCF-7 cells, respectively.{37040} It is a selective inhibitor of PKC (IC50 = 600-1,300 nM) with no activity on PKA or PPK at concentrations over 180 µM.{37039}
Brand:CaymanSKU:22175 -Out of stock
Cerdulatinib is a dual inhibitor of spleen tyrosine kinase (Syk) and Janus kinases (JAK; IC50s = 32, 12, 6, 8, and 0.5 nM for Syk, JAK1, JAK2, JAK3, and TYK2, respectively) and also exhibits nanomolar inhibition of other kinases.{34576} Syk is involved in the B cell receptor (BCR) pathway, and cerdulatinib inhibits downstream Syk-mediated signaling of ERK Y204 phosphorylation (IC50 = 0.5 μM), upregulates cell surface expression of CD69 (IC50 = 0.11 μM), and inhibits FcεRI-mediated basophil degranulation (IC50 = 0.12 μM).{34576} JAK is involved in JAK-STAT regulation of cytokine receptors. Cerdulatinib inhibits STAT3, STAT5, and STAT6 phosphorylation by interleukin-activated JAK1/3 with IC50 values ranging from 0.16 to 1 μM.{34576} Cerdulatinib disrupts JAK1/3-mediated signaling more selectively than JAK2 signaling (IC50 > 4 μM).{34576} Cerdulatinib displays potent antitumor activity against ABC and GCB types of diffuse large B cell lymphoma (DLBCL) by inducing apoptosis via caspase-2 and poly(ADP-ribose) polymerase (PARP) cleavage.{34577} Cerdulatinib exhibits IC50 values ranging from 0.05 to 2.1 μM against a panel of DLBCL tumor cell lines.{34577}
Brand:CaymanSKU:20076 -Available on backorder
Cerdulatinib is a dual inhibitor of spleen tyrosine kinase (Syk) and Janus kinases (JAK; IC50s = 32, 12, 6, 8, and 0.5 nM for Syk, JAK1, JAK2, JAK3, and TYK2, respectively) and also exhibits nanomolar inhibition of other kinases.{34576} Syk is involved in the B cell receptor (BCR) pathway, and cerdulatinib inhibits downstream Syk-mediated signaling of ERK Y204 phosphorylation (IC50 = 0.5 μM), upregulates cell surface expression of CD69 (IC50 = 0.11 μM), and inhibits FcεRI-mediated basophil degranulation (IC50 = 0.12 μM).{34576} JAK is involved in JAK-STAT regulation of cytokine receptors. Cerdulatinib inhibits STAT3, STAT5, and STAT6 phosphorylation by interleukin-activated JAK1/3 with IC50 values ranging from 0.16 to 1 μM.{34576} Cerdulatinib disrupts JAK1/3-mediated signaling more selectively than JAK2 signaling (IC50 > 4 μM).{34576} Cerdulatinib displays potent antitumor activity against ABC and GCB types of diffuse large B cell lymphoma (DLBCL) by inducing apoptosis via caspase-2 and poly(ADP-ribose) polymerase (PARP) cleavage.{34577} Cerdulatinib exhibits IC50 values ranging from 0.05 to 2.1 μM against a panel of DLBCL tumor cell lines.{34577}
Brand:CaymanSKU:20076 -Available on backorder
Cerdulatinib is a dual inhibitor of spleen tyrosine kinase (Syk) and Janus kinases (JAK; IC50s = 32, 12, 6, 8, and 0.5 nM for Syk, JAK1, JAK2, JAK3, and TYK2, respectively) and also exhibits nanomolar inhibition of other kinases.{34576} Syk is involved in the B cell receptor (BCR) pathway, and cerdulatinib inhibits downstream Syk-mediated signaling of ERK Y204 phosphorylation (IC50 = 0.5 μM), upregulates cell surface expression of CD69 (IC50 = 0.11 μM), and inhibits FcεRI-mediated basophil degranulation (IC50 = 0.12 μM).{34576} JAK is involved in JAK-STAT regulation of cytokine receptors. Cerdulatinib inhibits STAT3, STAT5, and STAT6 phosphorylation by interleukin-activated JAK1/3 with IC50 values ranging from 0.16 to 1 μM.{34576} Cerdulatinib disrupts JAK1/3-mediated signaling more selectively than JAK2 signaling (IC50 > 4 μM).{34576} Cerdulatinib displays potent antitumor activity against ABC and GCB types of diffuse large B cell lymphoma (DLBCL) by inducing apoptosis via caspase-2 and poly(ADP-ribose) polymerase (PARP) cleavage.{34577} Cerdulatinib exhibits IC50 values ranging from 0.05 to 2.1 μM against a panel of DLBCL tumor cell lines.{34577}
Brand:CaymanSKU:20076 -Available on backorder
Cerdulatinib is a dual inhibitor of spleen tyrosine kinase (Syk) and Janus kinases (JAK; IC50s = 32, 12, 6, 8, and 0.5 nM for Syk, JAK1, JAK2, JAK3, and TYK2, respectively) and also exhibits nanomolar inhibition of other kinases.{34576} Syk is involved in the B cell receptor (BCR) pathway, and cerdulatinib inhibits downstream Syk-mediated signaling of ERK Y204 phosphorylation (IC50 = 0.5 μM), upregulates cell surface expression of CD69 (IC50 = 0.11 μM), and inhibits FcεRI-mediated basophil degranulation (IC50 = 0.12 μM).{34576} JAK is involved in JAK-STAT regulation of cytokine receptors. Cerdulatinib inhibits STAT3, STAT5, and STAT6 phosphorylation by interleukin-activated JAK1/3 with IC50 values ranging from 0.16 to 1 μM.{34576} Cerdulatinib disrupts JAK1/3-mediated signaling more selectively than JAK2 signaling (IC50 > 4 μM).{34576} Cerdulatinib displays potent antitumor activity against ABC and GCB types of diffuse large B cell lymphoma (DLBCL) by inducing apoptosis via caspase-2 and poly(ADP-ribose) polymerase (PARP) cleavage.{34577} Cerdulatinib exhibits IC50 values ranging from 0.05 to 2.1 μM against a panel of DLBCL tumor cell lines.{34577}
Brand:CaymanSKU:20076 -Available on backorder
Cereblon ligand 1 is a building block in the synthesis of proteolysis-targeting chimera technologies (PROTACs).{40932}
Brand:CaymanSKU:21589 -Out of stock
Cereblon ligand 1 is a building block in the synthesis of proteolysis-targeting chimera technologies (PROTACs).{40932}
Brand:CaymanSKU:21589 -Out of stock
Cerebroside C is a fungal metabolite and glycosphingolipid that has been found in the rice pathogenic fungus M. grisea.{42945} It induces production of the phytoalexin momilactone A when applied to wounded rice leaves, indicating that cerebroside C is an elicitor of the hypersensitive response in rice. Cerebroside C increases germination rate and reduces germination time in wheat seeds in a concentration-dependent manner at 4°C.{42946} It also increases root length, fresh weight, and dry weight of wheat seedlings when used at a concentration of 20 μg/ml at 4°C, indicating increased chilling tolerance.
Brand:CaymanSKU:28590 - 1 mgAvailable on backorder
Cerestat is an NMDA receptor antagonist (IC50 = 36 nM).{52616} It is selective for the NMDA receptor over sigma receptors (IC50 = 2,540 nM). Cerestat (1 mg/kg) reduces infarct volume and the number of steps and errors in a foot fault test in a rat model of stroke induced by middle cerebral artery occlusion.{52617} It also reduces cortical and striatal neuronal necrosis in a rat model of temporary focal ischemia when administered at a dose of 1.13 mg/kg.{52618}
Brand:CaymanSKU:30966 - 1 mgAvailable on backorder
Cerestat is an NMDA receptor antagonist (IC50 = 36 nM).{52616} It is selective for the NMDA receptor over sigma receptors (IC50 = 2,540 nM). Cerestat (1 mg/kg) reduces infarct volume and the number of steps and errors in a foot fault test in a rat model of stroke induced by middle cerebral artery occlusion.{52617} It also reduces cortical and striatal neuronal necrosis in a rat model of temporary focal ischemia when administered at a dose of 1.13 mg/kg.{52618}
Brand:CaymanSKU:30966 - 5 mgAvailable on backorder
Cerevisterol is an ergosterol fungal metabolite originally isolated from S. cerevisiae that has diverse biological activities, including antimicrobial, anti-inflammatory, and anticancer properties.{45430} It is active against the bacteria S. typhi, S. aureus, and E. faecalis (MICs = 25, 25, and 50 µg/ml, respectively) and the fungus A. niger (MIC = 25 µg/ml), but has no effect on the bacteria E. coli, P. aeruginosa, S. pyogenes, K. pneumoniae, and B. subtilis, or the fungi C. albicans, A. flavus, and A. tamarii when used at concentrations up to 400 µg/ml.{45431} Cerevisterol (2-20 µM) inhibits LPS-induced increases in the levels of nitric oxide (NO), TNF-α, IL-6, IL-10, and prostaglandin E2 (PGE2; Item No. 14010) in RAW 264.7 cells.{45432} It inhibits proliferation of MCF-7, MDA-MB-231, and Caco-2 cancer cells (EC50s = 64.5, 52.4, and 37.6 µM, respectively), but not PC3, PANC-1, or A549 cells (IC50 = >100 µM for all).{45433},{45434}
Brand:CaymanSKU:28466 - 1 mgAvailable on backorder
Ceritinib is an inhibitor of anaplastic lymphoma kinase (ALK; IC50 = 0.2 nM).{48716} It is selective for ALK over IGF-1R, InsR, STK22D, and FLT3 (IC50s = 8, 7, 23, and 60 nM, respectively) as well as a panel of 25 additional kinases (IC50s = >0.26 μM for all). Ceritinib inhibits the proliferation of Ba/F3 cells expressing the fusion protein nucleophosmin-ALK (NPM-ALK) or echinoderm microtubule-associated protein-like 4-ALK (ELM4-ALK; IC50s = 0.02 and 0.021 μM, respectively), as well as several crizotinib-resistant NPM-ALK and ELM4-ALK mutants.{31295} It reduces tumor growth in an H2228 non-small cell lung cancer (NSCLC) rat xenograft model when administered at a dose of 10 mg/kg per day and induces tumor regression at 25 mg/kg per day.{48716} Ceritinib (25 and 50 mg/kg per day) also induces tumor regression in a Karpas299 lymphoma rat xenograft model. Formulations containing ceritinib have been used in the treatment of ALK-positive metastatic NSCLC.
Brand:CaymanSKU:-Available on backorder
Ceritinib is an inhibitor of anaplastic lymphoma kinase (ALK; IC50 = 0.2 nM).{48716} It is selective for ALK over IGF-1R, InsR, STK22D, and FLT3 (IC50s = 8, 7, 23, and 60 nM, respectively) as well as a panel of 25 additional kinases (IC50s = >0.26 μM for all). Ceritinib inhibits the proliferation of Ba/F3 cells expressing the fusion protein nucleophosmin-ALK (NPM-ALK) or echinoderm microtubule-associated protein-like 4-ALK (ELM4-ALK; IC50s = 0.02 and 0.021 μM, respectively), as well as several crizotinib-resistant NPM-ALK and ELM4-ALK mutants.{31295} It reduces tumor growth in an H2228 non-small cell lung cancer (NSCLC) rat xenograft model when administered at a dose of 10 mg/kg per day and induces tumor regression at 25 mg/kg per day.{48716} Ceritinib (25 and 50 mg/kg per day) also induces tumor regression in a Karpas299 lymphoma rat xenograft model. Formulations containing ceritinib have been used in the treatment of ALK-positive metastatic NSCLC.
Brand:CaymanSKU:-Available on backorder
Ceritinib is an inhibitor of anaplastic lymphoma kinase (ALK; IC50 = 0.2 nM).{48716} It is selective for ALK over IGF-1R, InsR, STK22D, and FLT3 (IC50s = 8, 7, 23, and 60 nM, respectively) as well as a panel of 25 additional kinases (IC50s = >0.26 μM for all). Ceritinib inhibits the proliferation of Ba/F3 cells expressing the fusion protein nucleophosmin-ALK (NPM-ALK) or echinoderm microtubule-associated protein-like 4-ALK (ELM4-ALK; IC50s = 0.02 and 0.021 μM, respectively), as well as several crizotinib-resistant NPM-ALK and ELM4-ALK mutants.{31295} It reduces tumor growth in an H2228 non-small cell lung cancer (NSCLC) rat xenograft model when administered at a dose of 10 mg/kg per day and induces tumor regression at 25 mg/kg per day.{48716} Ceritinib (25 and 50 mg/kg per day) also induces tumor regression in a Karpas299 lymphoma rat xenograft model. Formulations containing ceritinib have been used in the treatment of ALK-positive metastatic NSCLC.
Brand:CaymanSKU:-Available on backorder
Ceritinib is an inhibitor of anaplastic lymphoma kinase (ALK; IC50 = 0.2 nM).{48716} It is selective for ALK over IGF-1R, InsR, STK22D, and FLT3 (IC50s = 8, 7, 23, and 60 nM, respectively) as well as a panel of 25 additional kinases (IC50s = >0.26 μM for all). Ceritinib inhibits the proliferation of Ba/F3 cells expressing the fusion protein nucleophosmin-ALK (NPM-ALK) or echinoderm microtubule-associated protein-like 4-ALK (ELM4-ALK; IC50s = 0.02 and 0.021 μM, respectively), as well as several crizotinib-resistant NPM-ALK and ELM4-ALK mutants.{31295} It reduces tumor growth in an H2228 non-small cell lung cancer (NSCLC) rat xenograft model when administered at a dose of 10 mg/kg per day and induces tumor regression at 25 mg/kg per day.{48716} Ceritinib (25 and 50 mg/kg per day) also induces tumor regression in a Karpas299 lymphoma rat xenograft model. Formulations containing ceritinib have been used in the treatment of ALK-positive metastatic NSCLC.
Brand:CaymanSKU:-Available on backorder
Ceritinib-d7 is intended for use as an internal standard for the quantification of ceritinib (Item No. 19374) by GC- or LC-MS. Ceritinib is an inhibitor of anaplastic lymphoma kinase (ALK; IC50 = 0.2 nM).{48716} It is selective for ALK over IGF-1R, InsR, STK22D, and FLT3 (IC50s = 8, 7, 23, and 60 nM, respectively) as well as a panel of 25 additional kinases (IC50s = >0.26 μM for all). Ceritinib inhibits the proliferation of Ba/F3 cells expressing the fusion protein nucleophosmin-ALK (NPM-ALK) or echinoderm microtubule-associated protein-like 4-ALK (ELM4-ALK; IC50s = 0.02 and 0.021 μM, respectively), as well as several crizotinib-resistant NPM-ALK and ELM4-ALK mutants.{31295} It reduces tumor growth in an H2228 non-small cell lung cancer (NSCLC) rat xenograft model when administered at a dose of 10 mg/kg per day and induces tumor regression at 25 mg/kg per day.{48716} Ceritinib (25 and 50 mg/kg per day) also induces tumor regression in a Karpas299 lymphoma rat xenograft model. Formulations containing ceritinib have been used in the treatment of ALK-positive metastatic NSCLC.
Brand:CaymanSKU:28768 - 1 mgAvailable on backorder
Cerivastatin is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (Ki = 1.3 nM).{38752,38751} It inhibits cholesterol synthesis in and growth of human arterial myocytes (IC50s = 0.4 and 4.6 nM, respectively).{38752} Cerivastatin inhibits proliferation of rat aorta smooth muscle cells and reduces fibrinogen-induced migration of rat aortic myocytes in a concentration-dependent manner. In vivo, cerivastatin inhibits cholesterol biosynthesis in rats and dogs (ED50 = 0.002 mg/kg for both).{38751} It reduces serum levels of cholesterol, triglycerides, and low-density lipoprotein (LDL) in dogs in a dose-dependent manner. Cerivastatin (0.1 mg/kg) decreases cholesterol ester accumulation in arterial tissue of rabbits fed a 0.2% cholesterol diet. It also stabilizes plaques and delays progression into atherosclerotic disease in LDL-receptor deficient rabbits with hypercholesterolemia.{38753}
Brand:CaymanSKU:20362 -Available on backorder
Cerivastatin is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (Ki = 1.3 nM).{38752,38751} It inhibits cholesterol synthesis in and growth of human arterial myocytes (IC50s = 0.4 and 4.6 nM, respectively).{38752} Cerivastatin inhibits proliferation of rat aorta smooth muscle cells and reduces fibrinogen-induced migration of rat aortic myocytes in a concentration-dependent manner. In vivo, cerivastatin inhibits cholesterol biosynthesis in rats and dogs (ED50 = 0.002 mg/kg for both).{38751} It reduces serum levels of cholesterol, triglycerides, and low-density lipoprotein (LDL) in dogs in a dose-dependent manner. Cerivastatin (0.1 mg/kg) decreases cholesterol ester accumulation in arterial tissue of rabbits fed a 0.2% cholesterol diet. It also stabilizes plaques and delays progression into atherosclerotic disease in LDL-receptor deficient rabbits with hypercholesterolemia.{38753}
Brand:CaymanSKU:20362 -Available on backorder
Cerivastatin is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (Ki = 1.3 nM).{38752,38751} It inhibits cholesterol synthesis in and growth of human arterial myocytes (IC50s = 0.4 and 4.6 nM, respectively).{38752} Cerivastatin inhibits proliferation of rat aorta smooth muscle cells and reduces fibrinogen-induced migration of rat aortic myocytes in a concentration-dependent manner. In vivo, cerivastatin inhibits cholesterol biosynthesis in rats and dogs (ED50 = 0.002 mg/kg for both).{38751} It reduces serum levels of cholesterol, triglycerides, and low-density lipoprotein (LDL) in dogs in a dose-dependent manner. Cerivastatin (0.1 mg/kg) decreases cholesterol ester accumulation in arterial tissue of rabbits fed a 0.2% cholesterol diet. It also stabilizes plaques and delays progression into atherosclerotic disease in LDL-receptor deficient rabbits with hypercholesterolemia.{38753}
Brand:CaymanSKU:20362 -Available on backorder
A number of tumor cells and cell lines have been observed to have highly upregulated expression and activity of fatty acid synthase (FASN). Inhibition of FASN by the irreversible inhibitor cerulenin leads to cytotoxicity and apoptosis in human cancer cell lines,{11992} an effect believed to be mediated by the accumulation of malonyl-coenzyme A in cells with an upregulated FASN pathway.{11993} Cerulenin also leads to profound weight loss and feeding inhibition in both high-fat diet wild type obese and leptin-deficient ob/ob mice.{7659}
Brand:CaymanSKU:10005647 - 10 mgAvailable on backorder
A number of tumor cells and cell lines have been observed to have highly upregulated expression and activity of fatty acid synthase (FASN). Inhibition of FASN by the irreversible inhibitor cerulenin leads to cytotoxicity and apoptosis in human cancer cell lines,{11992} an effect believed to be mediated by the accumulation of malonyl-coenzyme A in cells with an upregulated FASN pathway.{11993} Cerulenin also leads to profound weight loss and feeding inhibition in both high-fat diet wild type obese and leptin-deficient ob/ob mice.{7659}
Brand:CaymanSKU:10005647 - 5 mgAvailable on backorder
A number of tumor cells and cell lines have been observed to have highly upregulated expression and activity of fatty acid synthase (FASN). Inhibition of FASN by the irreversible inhibitor cerulenin leads to cytotoxicity and apoptosis in human cancer cell lines,{11992} an effect believed to be mediated by the accumulation of malonyl-coenzyme A in cells with an upregulated FASN pathway.{11993} Cerulenin also leads to profound weight loss and feeding inhibition in both high-fat diet wild type obese and leptin-deficient ob/ob mice.{7659}
Brand:CaymanSKU:10005647 - 50 mgAvailable on backorder
The fibrate class of hypolipidemic drugs such as clofibrate and fenofibrate elicit their effects by binding to and activating peroxisome proliferator-activated receptor α (PPARα). Cetaben is a unique, peroxisome proliferator-activated receptor α (PPARα)-independent peroxisome proliferator with hypolipidemic activity, characterized by reduction in serum triglyceride and cholesterol concentrations in rats.{13454} In male wistar rats, cetaben increased the activity of all peroxisomal enzymes examined in liver and kidney, whereas clofibrate showed a varied regulatory pattern.{13450} In addition to its effects on peroxisomes, cetaben inhibits cholesterol synthesis in the human hepatoma HepG2 cells resulting in reversible changes in Golgi morphology.{13452,13453} It also blocked triglyceride synthesis by 99% and reduced cholesterol ester synthesis by >70% at a concentration of 50 µM in these same cells.{13453}
Brand:CaymanSKU:10007171 - 10 mgAvailable on backorder
The fibrate class of hypolipidemic drugs such as clofibrate and fenofibrate elicit their effects by binding to and activating peroxisome proliferator-activated receptor α (PPARα). Cetaben is a unique, peroxisome proliferator-activated receptor α (PPARα)-independent peroxisome proliferator with hypolipidemic activity, characterized by reduction in serum triglyceride and cholesterol concentrations in rats.{13454} In male wistar rats, cetaben increased the activity of all peroxisomal enzymes examined in liver and kidney, whereas clofibrate showed a varied regulatory pattern.{13450} In addition to its effects on peroxisomes, cetaben inhibits cholesterol synthesis in the human hepatoma HepG2 cells resulting in reversible changes in Golgi morphology.{13452,13453} It also blocked triglyceride synthesis by 99% and reduced cholesterol ester synthesis by >70% at a concentration of 50 µM in these same cells.{13453}
Brand:CaymanSKU:10007171 - 100 mgAvailable on backorder
The fibrate class of hypolipidemic drugs such as clofibrate and fenofibrate elicit their effects by binding to and activating peroxisome proliferator-activated receptor α (PPARα). Cetaben is a unique, peroxisome proliferator-activated receptor α (PPARα)-independent peroxisome proliferator with hypolipidemic activity, characterized by reduction in serum triglyceride and cholesterol concentrations in rats.{13454} In male wistar rats, cetaben increased the activity of all peroxisomal enzymes examined in liver and kidney, whereas clofibrate showed a varied regulatory pattern.{13450} In addition to its effects on peroxisomes, cetaben inhibits cholesterol synthesis in the human hepatoma HepG2 cells resulting in reversible changes in Golgi morphology.{13452,13453} It also blocked triglyceride synthesis by 99% and reduced cholesterol ester synthesis by >70% at a concentration of 50 µM in these same cells.{13453}
Brand:CaymanSKU:10007171 - 5 mgAvailable on backorder
The fibrate class of hypolipidemic drugs such as clofibrate and fenofibrate elicit their effects by binding to and activating peroxisome proliferator-activated receptor α (PPARα). Cetaben is a unique, peroxisome proliferator-activated receptor α (PPARα)-independent peroxisome proliferator with hypolipidemic activity, characterized by reduction in serum triglyceride and cholesterol concentrations in rats.{13454} In male wistar rats, cetaben increased the activity of all peroxisomal enzymes examined in liver and kidney, whereas clofibrate showed a varied regulatory pattern.{13450} In addition to its effects on peroxisomes, cetaben inhibits cholesterol synthesis in the human hepatoma HepG2 cells resulting in reversible changes in Golgi morphology.{13452,13453} It also blocked triglyceride synthesis by 99% and reduced cholesterol ester synthesis by >70% at a concentration of 50 µM in these same cells.{13453}
Brand:CaymanSKU:10007171 - 50 mgAvailable on backorder
Cetilistat is an inhibitor of pancreatic lipase (IC50s = 5.95 and 54.8 nM for the human and rat enzymes, respectively).{61090} It reduces increases in plasma triglyceride levels in an oral fat tolerance test, indicating decreased intestinal fat absorption, in rats when administered at a doses ranging from 3 to 100 mg/kg. Dietary administration of cetilistat (4.9-50.7 mg/kg per day) decreases body weight gain without affecting food intake, as well as reduces increases in plasma triglyceride and leptin levels in a rat model of high-fat diet-induced obesity. It also reduces viral load in the culture supernatant of Vero E6 cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; EC90 = 2.9 µM) and inhibits SARS-CoV-2 replication in a plaque reduction assay (EC50 = 1.13 µM).{59330}
Brand:CaymanSKU:31622 - 10 gAvailable on backorder
Cetilistat is an inhibitor of pancreatic lipase (IC50s = 5.95 and 54.8 nM for the human and rat enzymes, respectively).{61090} It reduces increases in plasma triglyceride levels in an oral fat tolerance test, indicating decreased intestinal fat absorption, in rats when administered at a doses ranging from 3 to 100 mg/kg. Dietary administration of cetilistat (4.9-50.7 mg/kg per day) decreases body weight gain without affecting food intake, as well as reduces increases in plasma triglyceride and leptin levels in a rat model of high-fat diet-induced obesity. It also reduces viral load in the culture supernatant of Vero E6 cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; EC90 = 2.9 µM) and inhibits SARS-CoV-2 replication in a plaque reduction assay (EC50 = 1.13 µM).{59330}
Brand:CaymanSKU:31622 - 100 gAvailable on backorder
Cetilistat is an inhibitor of pancreatic lipase (IC50s = 5.95 and 54.8 nM for the human and rat enzymes, respectively).{61090} It reduces increases in plasma triglyceride levels in an oral fat tolerance test, indicating decreased intestinal fat absorption, in rats when administered at a doses ranging from 3 to 100 mg/kg. Dietary administration of cetilistat (4.9-50.7 mg/kg per day) decreases body weight gain without affecting food intake, as well as reduces increases in plasma triglyceride and leptin levels in a rat model of high-fat diet-induced obesity. It also reduces viral load in the culture supernatant of Vero E6 cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; EC90 = 2.9 µM) and inhibits SARS-CoV-2 replication in a plaque reduction assay (EC50 = 1.13 µM).{59330}
Brand:CaymanSKU:31622 - 25 gAvailable on backorder